AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18696272 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale (NIHSS) scores
Number of subjects: 820
Study 16965740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Kang'ai Granules combined with super-selective intra-arterial chemotherapy (EAP regime: VP(16) 100 mg/m(2) + epirubicin 60 mg/m(2) + carboplatin 200 mg/m(2))
Number of subjects: 40
Study 16965740 — intervention group
Group type: COMPARATOR
Intervention: Control group (super-selective intra-arterial chemotherapy only)
Number of subjects: 40
Study 12942015 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Risk Assessment Method
Number of subjects: 221
Study 12942015 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire
Number of subjects: 221
Study 10896068 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 132
Study 10896068 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 132
Study 9290168 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment for 3 months
Number of subjects: 13
Study 9290168 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy volunteers)
Number of subjects: 13
Study 8497820 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment at a steady state plasma concentration of 17 mg/l
Number of subjects: 15
Study 8497820 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment at a steady state plasma concentration of 10 mg/l
Number of subjects: 15
Study 8497820 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 15
Study 3126683 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (group A)
Number of subjects: 102
Study 3126683 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation (group B)
Number of subjects: 102
Study 29520080 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function (LOF) carriers
Number of subjects: 1476
Study 29520080 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 1476
Study 28570163 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-access online care
Number of subjects: 156
Study 28570163 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 156
Study 24704421 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking
Number of subjects: 10
Study 24704421 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 10
Study 24704421 — intervention group
Group type: COMPARATOR
Intervention: Standing every 20 min
Number of subjects: 10
Study 23076837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program, which consists of mentoring and skills groups
Number of subjects: 156
Study 23076837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 156
Study 21418055 — intervention group
Group type: EXPERIMENTAL
Intervention: computer‐assessed reading intervention (n=25)
Number of subjects: 166
Study 21418055 — intervention group
Group type: EXPERIMENTAL
Intervention: regular remedial reading intervention (n=25)
Number of subjects: 166
Study 21418055 — intervention group
Group type: COMPARATOR
Intervention: mainstream reading instruction (n=116)
Number of subjects: 166
Study 18790817 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (240 ml/day)
Number of subjects: 78
Study 18790817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka (80 ml/day)
Number of subjects: 78
Study 18790817 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Red wine and Vodka)
Number of subjects: 78
Study 16567032 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer crowns with glass-fiber framework
Number of subjects: 120
Study 16567032 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer crowns without fiber reinforcement
Number of subjects: 120
Study 16567032 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 120
Study 12589387 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg)
Number of subjects: 8
Study 12589387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11074805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine
Number of subjects: 32
Study 11074805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine (Sjögren subgroup)
Number of subjects: 32
Study 11074805 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 32
Study 11074805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine
Number of subjects: 32
Study 8826949 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 41802
Study 8826949 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection of prostate carcinoma via PSA screening
Number of subjects: 41802
Study 1576060 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine inhalation
Number of subjects: 15
Study 1576060 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline (placebo)
Number of subjects: 15
Study 3930437 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-baked gliadin-containing gluten-free bread, 6 slices daily for 6 weeks
Number of subjects: 10
Study 3930437 — intervention group
Group type: COMPARATOR
Intervention: Control period (not specified)
Number of subjects: 10
Study 31399454 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 8 weeks, twice a day, 5 days a week, with weekly physiotherapist visits; unsupervised IMT twice a day three times a week until follow-up at 6 months.
Number of subjects: 11
Study 29294598 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + methotrexate (MTX)
Number of subjects: 127
Study 29294598 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 127
Study 27791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA)
Number of subjects: 226
Study 27791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished patients (assessed by MNA)
Number of subjects: 226
Study 27791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at risk for malnutrition (assessed by MNA)
Number of subjects: 226
Study 27791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-nourished patients (assessed by MNA)
Number of subjects: 226
Study 24372085 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-tablet based intervention providing tailored information about breast cancer risk
Number of subjects: 1261
Study 22469449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice daily
Number of subjects: 728
Study 22469449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg once daily
Number of subjects: 728
Study 21446627 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour drain clamping
Number of subjects: 50
Study 21446627 — intervention group
Group type: COMPARATOR
Intervention: Continuous drainage
Number of subjects: 50
Study 18852401 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 458
Study 18852401 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 458
Study 16102631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) infusion for 20 days
Number of subjects: 87
Study 16102631 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 20 days
Number of subjects: 87
Study 16102631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) infusion
Number of subjects: 87
Study 16102631 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 87
Study 12420730 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous metronidazole 500 mg preoperatively
Number of subjects: 50
Study 12420730 — intervention group
Group type: COMPARATOR
Intervention: Multi-drug regimen (intravenous cefuroxime 1.5 g and metronidazole 0.5 g preoperatively, and oral co-amoxiclav 375 mg 8-hourly postoperatively)
Number of subjects: 50
Study 10626589 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital hypothyroidism (CH) group
Number of subjects: 100
Study 10626589 — intervention group
Group type: COMPARATOR
Intervention: Control group (siblings, classmates, and matched controls for age and gender)
Number of subjects: 100
Study 10626589 — intervention group
Group type: EXPERIMENTAL
Intervention: CH group
Number of subjects: 100
Study 7719242 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP (Vincristine, BCNU, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 0
Study 7719242 — intervention group
Group type: COMPARATOR
Intervention: VBMCP alternating with interferon
Number of subjects: 0
Study 7719242 — intervention group
Group type: COMPARATOR
Intervention: VBMCP with intermittent high dose cyclophosphamide
Number of subjects: 0
Study 8250105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg)
Number of subjects: 21
Study 8250105 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg)
Number of subjects: 21
Study 3540871 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg
Number of subjects: 198
Study 3540871 — intervention group
Group type: EXPERIMENTAL
Intervention: codeine sulfate 60 mg
Number of subjects: 198
Study 3540871 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg with codeine sulfate 60 mg
Number of subjects: 198
Study 3540871 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin 650 mg
Number of subjects: 198
Study 3540871 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198
Study 3540871 — intervention group
Group type: EXPERIMENTAL
Intervention: codeine-containing treatments
Number of subjects: 198
Study 29914432 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal schizotypal personality disorder symptoms
Number of subjects: 112
Study 29914432 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal borderline personality disorder symptoms
Number of subjects: 112
Study 27494629 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) applied to one painful finger in 3 sessions with one-week intervals.
Number of subjects: 4
Study 27494629 — intervention group
Group type: COMPARATOR
Intervention: Control finger (untreated)
Number of subjects: 4
Study 27494629 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) applied to one painful finger.
Number of subjects: 4
Study 24997351 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (ice cold water)
Number of subjects: 120
Study 24997351 — intervention group
Group type: COMPARATOR
Intervention: No stress (warm water)
Number of subjects: 120
Study 24997351 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressed female ADRA2B deletion carriers
Number of subjects: 120
Study 22162577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen
Number of subjects: 235
Study 22162577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 235
Study 22162577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents (low-dose tamoxifen and fenretinide)
Number of subjects: 235
Study 22162577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 21171297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray specific immunotherapy
Number of subjects: 36
Study 21171297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy
Number of subjects: 36
Study 21171297 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 36
Study 18539093 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of vaginal misoprostol
Number of subjects: 45
Study 18539093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15640254 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery followed by clomiphene citrate (CC)
Number of subjects: 83
Study 12910374 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 10,000 IE subcutaneously three times a week
Number of subjects: 60
Study 12910374 — intervention group
Group type: COMPARATOR
Intervention: Control (no epoetin)
Number of subjects: 60
Study 12910374 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 60
Study 9613780 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 42
Study 9613780 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplantation
Number of subjects: 42
Study 7914962 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid plus norfloxacin (13‐15 mg/kg and 400 mg, daily)
Number of subjects: 20
Study 2847465 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 U(anti-FXa)/kg Fragmin injected twice daily
Number of subjects: 0
Study 2847465 — intervention group
Group type: COMPARATOR
Intervention: 240 U/kg, 12 h standard heparin as continuous infusion
Number of subjects: 0
Study 2847465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 0
Study 30604337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent galvanic stimulation to bilateral masseter muscles for 5 days/week, for 4 weeks combined with conventional dysphagia rehabilitation
Number of subjects: 102
Study 30604337 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with conventional dysphagia rehabilitation
Number of subjects: 102
Study 29656504 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1501D
Number of subjects: 558
Study 29656504 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 558
Study 29656504 — intervention group
Group type: COMPARATOR
Intervention: MYL‐1501D and Insulin glargine
Number of subjects: 558
Study 28886751 — intervention group
Group type: EXPERIMENTAL
Intervention: Uva-ursi + advice to take ibuprofen
Number of subjects: 328
Study 28886751 — intervention group
Group type: COMPARATOR
Intervention: Placebo + advice to take ibuprofen
Number of subjects: 328
Study 28886751 — intervention group
Group type: EXPERIMENTAL
Intervention: Uva-ursi + no advice to take ibuprofen
Number of subjects: 328
Study 28886751 — intervention group
Group type: COMPARATOR
Intervention: Placebo + no advice to take ibuprofen
Number of subjects: 328
Study 28886751 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 328
Study 26336731 — intervention group
Group type: EXPERIMENTAL
Intervention: Total broncho-alveolar lavage
Number of subjects: 0
Study 24101768 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude treatment (≥ 2000 m)
Number of subjects: 958
Study 24101768 — intervention group
Group type: COMPARATOR
Intervention: Low altitude treatment (<2000 m)
Number of subjects: 958
Study 21390432 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 35
Study 21390432 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath Stacking (BS)
Number of subjects: 35
Study 21390432 — intervention group
Group type: COMPARATOR
Intervention: Exercise Control (EC)
Number of subjects: 35
Study 18460557 — intervention group
Group type: EXPERIMENTAL
Intervention: COM (MET 1000 mg BID, EX 10 microg BID)
Number of subjects: 60
Study 18460557 — intervention group
Group type: EXPERIMENTAL
Intervention: EX (10 microg BID)
Number of subjects: 60
Study 18460557 — intervention group
Group type: EXPERIMENTAL
Intervention: MET (1000 mg BID)
Number of subjects: 60
Study 16434984 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 63
Study 16434984 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2/HDC
Number of subjects: 63
Study 12946090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity 12-month intervention
Number of subjects: 386
Study 11078770 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (750 mg every 12 hours) and azithromycin (500 mg on day 1 and 250 mg per day thereafter) for seven days
Number of subjects: 58
Study 11078770 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg every 8 hours) and quinine (650 mg every 8 hours) for seven days
Number of subjects: 58
Study 9329303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment (200,000 IU for infants, 400,000 IU for 1-4 year olds)
Number of subjects: 472
Study 9329303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 8518642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mother intervention (monthly visits during the first year)
Number of subjects: 262
Study 8518642 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mother intervention
Number of subjects: 262
Study 8518642 — intervention group
Group type: COMPARATOR
Intervention: Standard support from public health nurse (Control)
Number of subjects: 262
Study 3559811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol supplementation (40 mg/kg every 6 hours)
Number of subjects: 48
Study 3559811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3559811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol supplementation
Number of subjects: 48
Study 29920085 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of pulses (white beans, chickpeas, and lentils)
Number of subjects: 11
Study 27048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional NiTi archwires
Number of subjects: 42
Study 27048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper NiTi (NiTiCu) archwires
Number of subjects: 42
Study 27048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy-coated NiTi archwires
Number of subjects: 42
Study 26578039 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal confocal microscopy (CCM)
Number of subjects: 26
Study 26578039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber density (IENFD)
Number of subjects: 26
Study 23401478 — intervention group
Group type: EXPERIMENTAL
Intervention: Training that reinforces the association between Blacks and danger (Experiment 2a and 2b)
Number of subjects: 0
Study 23401478 — intervention group
Group type: EXPERIMENTAL
Intervention: Training that eliminates bias by focusing on diagnostic object information (gun vs. no gun)
Number of subjects: 0
Study 23401478 — intervention group
Group type: COMPARATOR
Intervention: Reading about Black criminals (Experiment 1)
Number of subjects: 0
Study 23401478 — intervention group
Group type: COMPARATOR
Intervention: Reading about White criminals (Experiment 1)
Number of subjects: 0
Study 23401478 — intervention group
Group type: COMPARATOR
Intervention: Expert training and police officer experience
Number of subjects: 0
Study 21541451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training during hemodialysis, performed for 12 weeks, three times weekly.
Number of subjects: 22
Study 21541451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training during hemodialysis for 12 weeks.
Number of subjects: 22
Study 21541451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic training).
Number of subjects: 22
Study 19065902 — intervention group
Group type: EXPERIMENTAL
Intervention: Propyl gallate (PrG) in combination with standard medication
Number of subjects: 55
Study 19065902 — intervention group
Group type: COMPARATOR
Intervention: Salvia composite (SC) in combination with standard medication
Number of subjects: 55
Study 16898901 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug exposure (provocation tests)
Number of subjects: 10
Study 16898901 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure (provocation tests)
Number of subjects: 10
Study 16898901 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall psychological reactions during testing
Number of subjects: 10
Study 12860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus a 24-hour infusion of paclitaxel 135 mg/m2 (arm I)
Number of subjects: 792
Study 12860964 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m2 over 3 hours (arm II)
Number of subjects: 792
Study 10026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (N‐acetyl‐5‐methoxytryptamine) applied after UVR exposure
Number of subjects: 0
Study 10026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha‐tocopherol) applied after UVR exposure
Number of subjects: 0
Study 10026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid) applied after UVR exposure
Number of subjects: 0
Study 10026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antioxidants applied after UVR exposure
Number of subjects: 0
Study 10026402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple applications of antioxidants (three times: 30 min, 1 h and 2 h after irradiation)
Number of subjects: 0
Study 9048259 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturate-rich butter and cheese (B)
Number of subjects: 30
Study 9048259 — intervention group
Group type: COMPARATOR
Intervention: Normal butter and cheese (A)
Number of subjects: 30
Study 9048259 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturate-rich spread and cheese (C)
Number of subjects: 30
Study 1649725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 300 mg
Number of subjects: 15
Study 1649725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 600 mg
Number of subjects: 15
Study 1649725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6983719 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical spinal cord stimulation
Number of subjects: 11
Study 30353121 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1,000 mg injections 3 times per week after each hemodialysis session)
Number of subjects: 91
Study 30353121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 91
Study 29861021 — intervention group
Group type: EXPERIMENTAL
Intervention: RR+RR (same passage seven times)
Number of subjects: 130
Study 29861021 — intervention group
Group type: EXPERIMENTAL
Intervention: RR+Guided Wide Reading (one passage four times and three passages each once)
Number of subjects: 130
Study 29861021 — intervention group
Group type: EXPERIMENTAL
Intervention: GWR+GWR (seven passages each once)
Number of subjects: 130